Trials / Withdrawn
WithdrawnNCT06759740
An Exploratory Study of 68Ga-DOTA-SEMA in Preoperative Precise Imaging of Patients with Glucagon-Like Peptide-1 Receptor (GLP1R) Positive Insulinomas
- Status
- Withdrawn
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- The Affiliated Hospital Of Southwest Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Traditional imaging techniques for insulinomas have a low detection rate. This study aims to evaluate the safety, internal radiation dosimetry, and targeted imaging capability of the novel GLP1R imaging agent, 68Ga-DOTA-SEMA, in patients with GLP1R-positive insulinomas.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | 68Ga-DOTA-SEMA | 68Ga-DOTA-SEMA is GLP1R imaging agent |
Timeline
- Start date
- 2026-01-01
- Primary completion
- 2026-12-01
- Completion
- 2026-12-01
- First posted
- 2025-01-06
- Last updated
- 2025-03-14
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06759740. Inclusion in this directory is not an endorsement.